Altered timing of riboflavin and ultraviolet light pathogen inactivation improves platelet in vitro quality

Transfusion

Volumn 57, Issue 8, 2017, Pages 2026-2034

  Schubert, Peter ^a,b,c   Culibrk, Brankica ^a,b   Karwal, Simrath ^a,b   Serrano, Katherine ^a,b,c   Levin, Elena ^a,b,c   Yi, QiLong ^a   Thiele, Thomas ^d   Greinacher, Andreas ^d   Marschner, Susanne ^e   Devine, Dana V ^a,b,c  

^a CANADIAN BLOOD SERVICES   (Canada)

^b Centre for Blood Research   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e Terumo BCT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RIBOFLAVIN; THROMBOCYTE FACTOR 4; THROMBOSPONDIN;

ARTICLE; BLOOD BANK; CELL LYSATE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PATHOGEN INACTIVATION; PLATELET MICROPARTICLE; PLATELET QUALITY; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION AND CHARACTERISTICS; THROMBOCYTE METABOLISM; THROMBOCYTE PRESERVATION; THROMBOCYTOPHERESIS; ULTRAVIOLET RADIATION; BLOOD SAFETY; DRUG EFFECTS; PROCEDURES; QUALITY CONTROL; RADIATION RESPONSE; THROMBOCYTE; TIME FACTOR; VIROLOGY; VIRUS INACTIVATION;

BLOOD PLATELETS; BLOOD SAFETY; HUMANS; QUALITY CONTROL; RIBOFLAVIN; TIME FACTORS; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 85018914603     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14159     Document Type: Article

References (29)

1. Savage WJ. Transfusion reactions. Hematol Oncol Clin North Am 2016;30:619-34.
2. Blajchman MA, Beckers EA, Dickmeiss E, et al. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005;19:259-72.
3. Mathai J. Problem of bacterial contamination in platelet concentrates. Transfus Apher Sci 2009;41:139-44.
4. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013;104:183-99.
5. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014;41:309-25.
6. Salunkhe V, van der Meer PF, de Korte D, et al. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apher Sci 2015;52:19-34.
7. Devine DV, Schubert P. Pathogen inactivation technologies: the advent of pathogen-reduced blood components to reduce blood safety risk. Hematol Oncol Clin North Am 2016;30:609-17.
8. Allain JP, Owusu-Ofori AK, Assennato SM, et al. Effect of plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016;387:1753-61.
9. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev 2005;18:195-204.
10. Kaiser-Guignard J, Canellini G, Lion N, et al. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014;28:235-41.
11. Lozano M, Cid J. Platelet concentrates: balancing between efficacy and safety? Presse Med 2016;45:e289-98.
12. Chen Z, Schubert P, Culibrk B, et al. p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment. Transfusion 2015;55:848-57.
13. Schubert P, Culibrk B, Coupland D, et al. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012;52:397-408.
14. Cognasse F, Osselaer JC, Payrat JM, et al. Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion 2008;48:809-13.
15. Prudent M, D'Alessandro A, Cazenave JP, et al. Proteome changes in platelets after pathogen inactivation—an interlaboratory consensus. Transfus Med Rev 2014;28:72-83.
16. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-41.
17. Snyder E, Raife T, Lin L, et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004;44:1732-40.
18. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362-75.
19. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004;104:1534-41.
20. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
21. Tauszig ME, Picker SM, Gathof BS. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction. Transfus Apher Sci 2012;46:33-7.
22. Schubert P, Coupland D, Culibrk B, et al. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 2013;53:3164-73.
23. Rinder HM, Snyder EL, Tracey JB, et al. Reversibility of severe metabolic stress in stored platelets after in vitro plasma rescue or in vivo transfusion: restoration of secretory function and maintenance of platelet survival. Transfusion 2003;43:1230-7.
24. Rudderow D, Soslau G. Permanent lesions of stored platelets correlate to pH and cell count while reversible lesions do not. Proc Soc Exp Biol Med 1998;217:219-27.
25. Thiele T, Steil L, Gebhard S, et al. Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion 2007;47:1221-33.
26. Goodrich RP, Gilmour D, Hovenga N, et al. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009;49:1205-16.
27. Wagner SJ, Moroff G, Katz AJ, et al. Comparison of bacteria growth in single and pooled platelet concentrates after deliberate inoculation and storage. Transfusion 1995;35:298-302.
28. Wagner SJ, Benjamin RJ, Hapip CA, et al. Investigation of bacterial inactivation in apheresis platelets with 24 or 30 hours between inoculation and inactivation. Vox Sang 2016;111:226-34.
29. Keil SD, Hovenga N, Gilmour D, et al. Treatment of platelet products with riboflavin and UV light: effectiveness against high titer bacterial contamination. J Vis Exp 2015;102:e52820.